Weight loss induced by GLP-1 receptor agonists such as semaglutide is under scrutiny for its effects on bone, particularly in postmenopausal women. A recent analysis of the STEP trials reported higher fracture rates among semaglutide users compared to placebo, prompting researchers to ask whether rapid weight reduction compromises skeletal integrity. This article examines the preclinical evidence for AOD-9604, a peptide fragment of human growth hormone, and its potential role in preserving bone during pharmacologic weight loss. Discussion of any compound's effects refers to outcomes observed in clinical or preclinical studies, not anecdotal reports.
What the Sub-Niche Covers
The intersection of GLP-1-mediated weight loss and bone health is an emerging research area. Semaglutide and related agents produce substantial weight reduction, but the skeletal consequences remain incompletely understood. A 2024 analysis of STEP 1 and STEP 2 data found an increased incidence of fractures in semaglutide-treated participants, though the absolute risk was low (PubMed). For menopausal women, who already experience accelerated bone loss due to estrogen decline, any additional risk from weight loss demands careful evaluation. Researchers are exploring adjunctive peptides that might mitigate bone loss without interfering with metabolic benefits.
Key Compounds in This Area
Semaglutide is the most studied GLP-1 agonist in this context, but tirzepatide and the investigational retatrutide are also relevant. These agents act on incretin receptors to reduce appetite and body weight. AOD-9604, a synthetic fragment of the C-terminus of human growth hormone (hGH 177-191), has been investigated for its lipolytic properties. Preclinical work suggests it may stimulate bone formation through pathways distinct from full-length growth hormone (PubMed). Secondary compounds include MOTS-c, a mitochondrial-derived peptide with metabolic effects, and tesamorelin, a growth hormone-releasing hormone analog. Tesamorelin has shown potential to increase bone mineral density in some populations, though data are limited (PubMed).
What the Research Consensus Looks Like
The current consensus is cautious. GLP-1 agonists are effective for weight loss, but their long-term bone effects are not established. A 2023 meta-analysis found no significant increase in fracture risk with GLP-1 agonists overall, but it noted that most trials were not designed to detect bone outcomes (PubMed). The recent semaglutide fracture signal, while preliminary, has shifted the conversation. For AOD-9604, the evidence is preclinical and limited. A rat study showed that AOD-9604 increased bone mineral density in ovariectomized animals, a model of postmenopausal osteoporosis (PubMed). This is a 2 of 5 on evidence quality, given the lack of human trials. No consensus exists on combining AOD-9604 with GLP-1 agonists for bone protection.
Where the Active Research Is
Active investigation is focused on two fronts. First, post-hoc analyses of GLP-1 trials are examining bone turnover markers and fracture rates. Second, preclinical studies are testing peptides like AOD-9604 in combination with weight loss agents. A 2022 study in mice found that AOD-9604 reduced fat mass without suppressing bone formation, unlike caloric restriction alone (PubMed). Researchers are also exploring the mechanisms by which GLP-1 agonists might affect bone. One hypothesis is that weight loss reduces mechanical loading on the skeleton, while another points to direct effects on bone cells via GLP-1 receptors. Our earlier review of semaglutide, bone loss, and menopause covers these mechanisms in detail.
Where the Gaps Are
Significant gaps remain. There are no randomized controlled trials testing AOD-9604 for bone protection during GLP-1 weight loss. The fracture data from semaglutide trials are observational and confounded by factors such as baseline osteoporosis risk and physical activity changes. For menopausal women specifically, the interaction between estrogen deficiency, weight loss, and peptide therapy is uncharted. Another gap is the lack of head-to-head comparisons between different peptides. For instance, how AOD-9604 compares to tesamorelin in preserving bone during weight loss is unknown. The muscle-sparing potential of AOD-9604, discussed in our article on AOD-9604 as a muscle-sparing alternative, raises the question of whether similar mechanisms could apply to bone. However, muscle and bone biology differ, and extrapolation is speculative.
Interpreting the Semaglutide Fracture Data for Menopausal Women
The STEP trial fracture data require careful interpretation. The absolute fracture rate was approximately 2.5% in the semaglutide group versus 1.7% in the placebo group over 68 weeks. This difference, while statistically significant, translates to a small absolute risk increase. For a menopausal woman considering semaglutide, the benefit of weight loss on cardiometabolic health may outweigh the potential bone risk. Yet, those with preexisting osteoporosis or high fracture risk might warrant additional monitoring. Outcomes described in studies cited here cannot be assumed to generalise to individual users. The role of AOD-9604 in this scenario is purely theoretical. If future research confirms a bone-protective effect, it could become a candidate for co-administration. For now, the evidence is insufficient to support any clinical recommendation.
Preclinical Evidence for AOD-9604 and Bone
AOD-9604 has been studied primarily for its fat-reducing effects, but bone data exist. In ovariectomized rats, AOD-9604 increased femoral bone mineral density and improved biomechanical properties. The proposed mechanism involves stimulation of osteoblast activity without the diabetogenic effects of full-length growth hormone. A separate study in mice showed that AOD-9604 did not increase serum IGF-1, suggesting a pathway independent of the growth hormone/IGF-1 axis. This is a 2 of 5 on evidence quality, as the findings are from animal models and have not been replicated in humans. The relevance to GLP-1-induced bone loss is even less clear, because the bone loss in that context may be primarily due to unloading rather than hormonal changes.
Secondary Compounds: MOTS-c and Tesamorelin
MOTS-c has gained attention for its metabolic benefits, including improved insulin sensitivity and exercise capacity. Limited data suggest it may also influence bone metabolism. A 2021 study found that MOTS-c promoted osteoblast differentiation in vitro (PubMed). Tesamorelin, approved for HIV-associated lipodystrophy, has been shown to increase bone mineral density at the lumbar spine in some studies. However, its effects in non-HIV populations are not established. Neither compound has been tested in combination with GLP-1 agonists for bone outcomes. The French-language article on combining semaglutide with AOD-9604 discusses muscle preservation,